Esperion Therapeutics | Sustainability Performance
Develops and commercializes therapies targeting cardiovascular and lipid-related conditions.
2008
United States
201 - 500 employees
Pharmaceuticals
$100M - 500M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#9275
Overall#2080
in United States#216
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$403.0MFY2025 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
11.7%FY2025
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
-9.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.1
▲ 0.8%
0.3
▲ 0.2%
0.4
▼ 3.5%
0.7
2031Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Available
Recycling policy
Not available
Workplace health & safety policy
Available
62%
Independent Directors
8 out of 13 incl. management
Overall score
27
Environment
4
Social
37
Governance
41
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
